anmelden
OMX Nordic 40
2.670,24
PKT
+52,29
PKT
+2,00
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Nordic 40-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 22.04.26 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 22.04.26 | ABB (Asea Brown Boveri) Hold | Jefferies & Company Inc. | |
| 22.04.26 | ABB (Asea Brown Boveri) Sector Perform | RBC Capital Markets | |
| 22.04.26 | ABB (Asea Brown Boveri) Hold | Jefferies & Company Inc. | |
| 22.04.26 | ABB (Asea Brown Boveri) Market-Perform | Bernstein Research | |
| 21.04.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 21.04.26 | Nokia Overweight | JP Morgan Chase & Co. | |
| 21.04.26 | Volvo (B) Overweight | JP Morgan Chase & Co. | |
| 20.04.26 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 20.04.26 | Novo Nordisk Hold | Jefferies & Company Inc. | |
| 20.04.26 | Hennes Mauritz (H M, H&M) Sector Perform | RBC Capital Markets | |
| 16.04.26 | Volvo (B) Market-Perform | Bernstein Research | |
| 15.04.26 | Nokia Buy | Deutsche Bank AG | |
| 15.04.26 | Volvo (B) Buy | Goldman Sachs Group Inc. | |
| 15.04.26 | Novo Nordisk Hold | Jefferies & Company Inc. | |
| 13.04.26 | ABB (Asea Brown Boveri) Equal Weight | Barclays Capital | |
| 10.04.26 | AstraZeneca Buy | UBS AG | |
| 10.04.26 | Novo Nordisk Neutral | UBS AG | |
| 10.04.26 | AstraZeneca Buy | Jefferies & Company Inc. | |
| 10.04.26 | ABB (Asea Brown Boveri) Neutral | UBS AG | |
| 09.04.26 | Volvo (B) Buy | UBS AG | |
| 08.04.26 | Nokia Buy | Jefferies & Company Inc. | |
| 07.04.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 02.04.26 | Hennes Mauritz (H M, H&M) Neutral | UBS AG | |
| 02.04.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 02.04.26 | Novo Nordisk Equal Weight | Barclays Capital | |
| 01.04.26 | Nokia Underweight | Barclays Capital | |
| 01.04.26 | Volvo (B) Overweight | JP Morgan Chase & Co. | |
| 31.03.26 | AstraZeneca Overweight | Barclays Capital | |
| 31.03.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 31.03.26 | AstraZeneca Buy | Jefferies & Company Inc. | |
| 31.03.26 | Novo Nordisk Neutral | Goldman Sachs Group Inc. | |
| 31.03.26 | Volvo (B) Buy | UBS AG | |
| 31.03.26 | Volvo (B) Market-Perform | Bernstein Research | |
| 31.03.26 | AstraZeneca Overweight | Barclays Capital | |
| 31.03.26 | ABB (Asea Brown Boveri) Hold | Jefferies & Company Inc. | |
| 30.03.26 | AstraZeneca Sell | Deutsche Bank AG | |
| 30.03.26 | Novo Nordisk Equal Weight | Barclays Capital | |
| 30.03.26 | Nokia Neutral | Goldman Sachs Group Inc. | |
| 30.03.26 | Hennes Mauritz (H M, H&M) Sector Perform | RBC Capital Markets |